AstraZeneca plc (LSE:AZN) (STO:AZN) (NYSE:AZN) said on Saturday that clinical trials for the potential COVID-19 vaccine AZD1222 have resumed in the UK after clearance from safety authorities.
The investigational vaccine was developed by the University of Oxford and its spin-out company, Vaccitech. Trials were paused on 6 September after a report of dangerous side effects. However, the study participant who suffered the adverse effects had reportedly been suffering neurological symptoms associated with a rare spinal inflammatory disorder called transverse myelitis, City A.M. reported.
The UK's Medicines Health Regulatory Authority (MHRA) has now confirmed that it is safe to resume the trials.
AstraZeneca has entered into agreements to supply almost three billion doses of the vaccine to governments across the world.
Bambusa Therapeutics names new CFO
Mabtech partners with Sai Life Sciences to expand access to EYRA multiplex immunology platform
Vimgreen Pharmaceuticals receives IND clearance for VG081821 in China
Inimmune reports dosing of first patient in Phase 2 allergen challenge chamber trial of INI-2004
Gesynta Pharma doses first patient in vipoglanstat Phase 2 clinical proof-of-concept trial
Immunic granted European patent for vidofludimus calcium dosing regimens
Biofrontera reports Phase 2b data for Ameluz photodynamic therapy in acne vulgaris treatment
Pfizer reports positive Phase 2 results for trispecific antibody in atopic dermatitis
Kelun-Biotech and Harbour BioMed receive China IND approval for atopic dermatitis therapy
Melodia Therapeutics reports award of US patent covering MLD-151
GSK to acquire 35Pharma for USD950m to strengthen cardiopulmonary pipeline
Gossamer Bio reports topline Phase 3 PROSERA results for seralutinib in PAH
Formosa Pharmaceuticals signs licensing deal with Arrotex for APP13007 in Australia and New Zealand